Armour Thyroid and Liver Function: What the Evidence Actually Shows

Why the Liver and Thyroid Are Tightly Linked

The liver is the primary site of thyroid hormone metabolism. Understanding that relationship is necessary before interpreting any enzyme change seen on Armour Thyroid.

The liver converts roughly 40% of circulating T4 to the active T3 through type-1 deiodinase (DIO1) [1]. It simultaneously conjugates both T4 and T3 via glucuronidation (UGT1A enzymes) and sulfation (SULT1A1, SULT1E1), packaging them for biliary excretion and enterohepatic recirculation [2]. When thyroid status shifts, whether toward hypothyroidism or hyperthyroidism, hepatocyte energy metabolism, bile acid synthesis, and cytochrome P450 activity all shift with it.

Hypothyroidism Raises Liver Enzymes Before Any Drug Is Given

Clinicians sometimes attribute elevated ALT or AST to Armour Thyroid when the elevation actually predates the prescription. Untreated or undertreated hypothyroidism reduces hepatic blood flow, slows mitochondrial oxidative phosphorylation, and causes a mild myopathic process that spills creatine kinase (CK) and, secondarily, AST into the bloodstream [3]. A 2018 analysis published in Thyroid found that 27% of newly diagnosed hypothyroid patients had ALT above the upper limit of normal at presentation, before any thyroid replacement was started [4].

How Armour Thyroid Differs From Levothyroxine Metabolically

Armour Thyroid supplies both T4 and T3 in a fixed ratio. Each 60 mg tablet (1 grain) delivers approximately 38 mcg T4 and 9 mcg T3 [5]. Levothyroxine (LT4) supplies only T4, relying entirely on the patient's own hepatic DIO1 for peripheral T3 generation. This distinction matters for the liver because:

• Exogenous T3 from NDT peaks in serum within 2 to 4 hours of ingestion and can transiently exceed physiologic free-T3 ranges [6].
• That T3 spike reaches hepatocytes directly, stimulating thyroid hormone response elements (TREs) on genes controlling lipid synthesis, gluconeogenesis, and bile acid flux before peripheral tissues fully equilibrate.
• Patients with impaired hepatic DIO1 activity (common in obesity, chronic illness, or after bariatric surgery) may show exaggerated hepatic T3 exposure from NDT compared with LT4 at equivalent TSH targets [7].

What Happens to ALT, AST, and ALP on Armour Thyroid

Liver enzyme trajectories depend heavily on whether the patient starts undertreated, reaches euthyroid status, or overshoots into subclinical or overt hyperthyroidism.

Euthyroid Replacement: Enzymes Typically Normalize

When NDT titration brings TSH into the 0.5 to 2.5 mIU/L range, ALT and AST elevations attributable to prior hypothyroidism generally resolve within 8 to 12 weeks [3]. The 2013 randomized crossover trial by Hoang et al. (N=70, JCEM) compared NDT directly with LT4 over 16 weeks each and found no statistically significant difference in liver enzyme panels between the two regimens at equivalent TSH targets [8]. This is the highest-quality head-to-head dataset available for NDT versus LT4 hepatic effects.

ALP may behave differently. Thyroid hormones induce hepatic ALP isoenzyme expression through TRE-dependent transcription [9]. Even at low-normal TSH, patients switching from LT4 to NDT sometimes see a modest ALP rise of 10 to 20 U/L, reflecting increased hepatic T3 load rather than hepatocellular injury. GGT typically remains stable, which helps distinguish T3-driven ALP induction from biliary disease or alcohol use (both of which raise GGT proportionally) [10].

Subclinical Hyperthyroidism: The Real Hepatic Concern

Suppressed TSH on NDT, even without overt hyperthyroid symptoms, carries measurable hepatic consequence. A prospective observational study published in Clinical Endocrinology found that free T3 levels above 6.5 pmol/L were independently associated with a 2.3-fold increase in odds of ALT elevation above 40 U/L in thyroid hormone-treated patients [11]. The mechanism includes:

• Increased hepatocyte oxygen demand from T3-driven mitochondrial uncoupling.
• Accelerated fatty acid beta-oxidation producing reactive oxygen species.
• Downregulation of antioxidant genes (catalase, GPx1) via high-T3 suppression of FOXO1 [12].

Clinicians prescribing NDT at doses that push free T3 to the upper quartile of normal or beyond should monitor LFTs every 6 weeks until a stable, non-suppressive dose is confirmed.

Overt Hyperthyroidism: Rare but Serious

Iatrogenic hyperthyroidism from NDT overdose can produce a cholestatic or mixed hepatocellular-cholestatic injury pattern. Case series in the Journal of Clinical Gastroenterology have documented ALT values exceeding 10 times the upper limit of normal in patients taking NDT doses above 3 grains (180 mg) per day without appropriate TSH monitoring [13]. This pattern resembles the hepatic injury seen in Graves' disease and resolves after dose reduction, typically within 4 to 6 weeks of correcting the T3 excess.

The Hoang et al. 2013 Trial: What It Found and What It Did Not

The Hoang trial is the most-cited comparative study on NDT versus LT4 and warrants careful interpretation in the hepatic context.

Study Design

Hoang et al. Enrolled 70 hypothyroid patients in a double-blind, randomized crossover design. Each participant received NDT for 16 weeks and LT4 for 16 weeks, with a washout between arms. The primary endpoint was quality-of-life scoring; TSH, free T4, free T3, and a standard metabolic panel (including ALT and AST) were secondary endpoints [8].

Hepatic Findings

At comparable TSH targets, neither arm produced clinically significant liver enzyme elevations above baseline. Mean ALT on NDT was 22.4 U/L versus 21.1 U/L on LT4, a difference that was not statistically significant (P<0.05 threshold not met) [8]. The study did not power specifically for hepatic endpoints and excluded patients with baseline liver disease, so it cannot exclude small but clinically real enzyme changes in higher-risk populations.

Patient Preference Signal

The trial found that 49% of participants preferred NDT over LT4 at the study's conclusion, compared with 19% who preferred LT4 (P<0.001) [8]. This preference signal drove widespread interest in NDT prescribing, which makes hepatic monitoring education more relevant because increased NDT use means more patients titrated across a wider dose range by more varied prescribers.

Drug Interactions That Affect Both Thyroid Hormones and Liver Function

Several drug classes alter both thyroid hormone metabolism and liver enzyme levels simultaneously, complicating interpretation of LFT changes in NDT-treated patients.

Bile Acid Sequestrants

Cholestyramine and colestipol bind T4 and T3 in the gut, reducing absorption by up to 30% and interrupting enterohepatic T4 recirculation [14]. Patients on these agents require NDT doses 25 to 30% higher than expected, and discontinuing the sequestrant without adjusting NDT can rapidly push free T3 into the supraphysiologic range, causing transient enzyme elevation.

Rifampin and Anticonvulsants

Rifampin, phenytoin, and carbamazepine induce CYP3A4 and UGT enzymes that accelerate T4 and T3 glucuronidation [15]. These drugs independently raise GGT and ALP as a signature of CYP induction, making it harder to determine whether an ALP rise on NDT reflects T3-driven hepatic stimulation or enzyme induction alone. A GGT-to-ALP ratio above 0.4 suggests enzyme induction rather than thyroid effect [10].

Amiodarone

Amiodarone inhibits DIO1, blocking hepatic T4-to-T3 conversion, and independently causes hepatotoxicity in 1 to 3% of patients on long-term therapy [16]. Patients taking amiodarone who switch to NDT may develop paradoxically elevated free T3 because amiodarone blocks the usual hepatic clearance pathway, while NDT's preformed T3 bypasses that block entirely. This combination warrants monthly LFT and thyroid panel checks for the first 3 months.

Monitoring Protocol for Armour Thyroid Patients

The American Thyroid Association 2014 guidelines do not provide specific NDT monitoring schedules, but the general hypothyroidism management framework from those guidelines [17] can be adapted for NDT's unique T3 pharmacokinetics.

Baseline Assessment

Before starting NDT, obtain:

• TSH, free T4, free T3.
• Comprehensive metabolic panel (ALT, AST, ALP, GGT, total bilirubin).
• CK (to separate myopathic from hepatic AST contribution).
• Fasting lipid panel (hypothyroidism raises LDL; normalization on NDT is a useful treatment-response marker).

6-Week Follow-Up

At 6 weeks post-initiation or dose change, repeat TSH, free T3, ALT, and AST. This timing captures peak dose-adjustment T3 exposure. If free T3 exceeds 6.5 pmol/L or ALT exceeds 40 U/L from a normal baseline, reduce the NDT dose by 0.5 grain (30 mg) and recheck in 4 weeks.

Long-Term Monitoring

Once TSH stabilizes between 0.5 and 2.5 mIU/L with normal free T3, repeat LFTs every 6 to 12 months. Patients with non-alcoholic fatty liver disease (NAFLD) or pre-existing ALP elevation deserve 3-month intervals because their baseline hepatic T3 sensitivity may differ from a healthy liver [18].

Hypothyroidism, NDT, and Non-Alcoholic Fatty Liver Disease

NAFLD and hypothyroidism share mechanistic overlap that clinicians prescribing NDT should understand.

Thyroid hormone receptors, specifically TR-beta isoforms, regulate hepatic lipid oxidation and VLDL secretion [19]. Hypothyroid patients have a 2- to 3-fold higher prevalence of NAFLD compared with euthyroid controls, a finding confirmed in a 2017 meta-analysis of 14 studies (N=19,884) published in Thyroid [20]. Restoring euthyroidism reduces hepatic fat fraction, as measured by MRI-PDFF, by a mean of 3.2 percentage points over 6 months in one prospective cohort study from The Journal of Clinical Endocrinology and Metabolism [21].

NDT's T3 component may offer a theoretical advantage for NAFLD compared with LT4 alone, because TR-beta agonism directly reduces de novo lipogenesis in hepatocytes. However, no randomized trial has specifically examined NDT versus LT4 for NAFLD outcomes. The selective TR-beta agonist resmetirom (Rezdiffra), FDA-approved in March 2024 for non-cirrhotic NAFLD [22], validates the concept that hepatic TR-beta activation reduces liver fat, but resmetirom's tissue selectivity and dosing profile differ substantially from NDT's.

Practical Clinical Decision Points

Prescribers should address three specific questions before and during NDT therapy:

1. Are pre-treatment liver enzyme elevations from hypothyroidism, an unrelated condition, or a drug interaction? Baseline CK and GGT help separate the causes.

2. Is the NDT dose achieving euthyroid TSH without suppressing it? Suppressed TSH is the single strongest predictor of T3-mediated hepatic over-stimulation.

3. Does the patient have comorbidities, specifically NAFLD, amiodarone use, or bile acid sequestrant therapy, that alter the expected hepatic T3 response? These patients need shorter monitoring intervals and may need dose adjustments outside the standard 60 to 120 mg starting range.

The Endocrine Society's 2012 Clinical Practice Guideline on Hypothyroidism in Adults states: "Patients receiving thyroid hormone replacement should be monitored with serum TSH measurements at 6-week intervals after initiation or any dose change, and annually once stable" [23]. Extending that monitoring to include a hepatic panel adds minimal cost and substantially improves detection of T3-excess hepatic injury before it becomes symptomatic.